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Abstract
Objectives: Repeated Waon therapy, which uses a far infrared-ray dry sauna system,
improved the vascular endothelial function and the cardiac function in patients with
chronic heart failure. In patients with chronic obstructive pulmonary disease (COPD),
pulmonary hypertension (PH) is associated with a poor prognosis. We investigated
whether repeated Waon therapy improves PH, cardiac function, exercise tolerance,
and the quality of life (QOL) in patients with COPD.
Methods: Consecutive 13 patients with COPD, who met the Global Initiative for
Chronic Obstructive Lung Disease criteria and had breathlessness despite receiving
conventional treatments, were recruited for this study. They underwent Waon ther-
apy at 60 ◦C in sauna for 15min following 30min warmth with blankets outside of
the sauna room. This therapy was performed once a day, for 4 weeks. Cardiac func-
tion, exercise tolerance, and St. George’s Respiratory Questionnaire (SGRQ) were
assessed before and 4 weeks after Waon therapy.
Results: Right ventricular positive dP/dt at rest elevated signiﬁcantly from 397± 266
to 512± 320mmHg/s (p = 0.024) after the therapy. While the PH at rest did not sig-
niﬁcantly decrease, the PH during exercise decreased signiﬁcantly from 64± 18 to
51± 13mmHg (p = 0.028) after Waon therapy. Furthermore, the therapy prolonged
the mean exercise time of the constant load of cycle ergometer exercise test
from 360± 107 to 392± 97 s (p = 0.032). The total scores of SGRQ improved from
59.7± 16.9 to 55.3± 17.2 (p = 0.002). In addition, no adverse effects were observed
related to Waon therapy.
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hronic obstructive pulmonary disease (COPD) is
chronic, debilitating and fatal lung disease.
any patients with COPD suffering from breathing-
elated problems in spite of receiving conventional
herapies such as medication, physical therapy and
xygen inhalation [1]. Therefore, there is a great
emand for the development of new therapies for
OPD.
In patients with COPD, pulmonary hypertension
PH) is associated with a poor prognosis. Remod-
ling of the pulmonary vessels is the principal
ausative factor of PH in COPD. PH is a common
omplication of COPD, and its presence is associ-
ted with shorter survival and worse clinical course
2]. However, severe PH at rest is uncommon in
atients with COPD [3]. Kessler et al. assessed the
volution of pulmonary hemodynamics in a group of
31 patients with moderate COPD who did not have
H at rest, although 76 patients (58%) developed PH
uring exercise [4].
We developed a form of thermal therapy,
amely Waon therapy (soothing warm therapy)
hat differs from the traditional sauna [5]. We
reviously reported that repeated Waon ther-
py improved the vascular endothelial function
n persons with risk factors for atherosclerosis
6]. Furthermore, this therapy improved the car-
iac function and exercise tolerance in patients
ith congestive heart failure, who suffered from
hronic symptoms despite the administration of
ull medications, and it was also performed safely
n patients with high risk [7,8]. These effects
re attributable to the reduction in the cardiac
reload and afterload [7]. We also have reported
hat the mechanism of improvement of vascular
unction due to an overexpression of endothe-
ial nitric oxide synthase (eNOS) in Syrian golden
amsters [9]. We consider that the eNOS upreg-
lation induced by sauna is caused by increases
n the cardiac output and blood ﬂow, which in
urn results in an increased shear stress. There-
ore, we expect that repeated Waon therapy may
elieve the symptoms in COPD patients by improving
H.
The present study investigated whether
epeated Waon therapy improves PH, cardiac
unction, exercise tolerance, and the quality of
ife (QOL) in patients with severe COPD.
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erance and the QOL in patients with severe COPD.
Ireland Ltd on behalf of Japanese College of Cardiology.
ubjects and methods
tudy group
e studied consecutive 13 patients with COPD who
atisﬁed the criteria of the Global Initiative for
hronic Obstructive Lung Disease (GOLD) guide-
ine (i.e. FEV1/FVC < 70% after bronchodilator agent
dministration). They had symptoms such as cough
nd dyspnea with grade 4 or 5 of Medical Research
ouncil (MRC) dyspnea scale in spite of conven-
ional treatments, no acute exacerbation of COPD
n the past 3 months and no signs of any respiratory
ract infection. All patients have already received
edications for COPD, such as inhaled 2-agonists,
nticholinergics and oral theophyllines. The medi-
ations and pulmonary rehabilitation programs had
ot been changed for at least 4 weeks before and
uring this study. Written informed consent was
btained from all of the patients before partici-
ation. This protocol was approved by the Ethics
ommittee of the Faculty of Medicine, Kagoshima
niversity.
aon therapy
aon therapy used a far infrared-ray dry sauna
hich is evenly maintained at 60 ◦C and differs from
raditional sauna. Waon therapy has an absence
f hydration pressure, and was performed as pre-
iously reported [7]. Brieﬂy, the patients were
laced in a supine position on a bed in a 60 ◦C
auna for 15min, and then after leaving the sauna,
hey were then underwent bed rest with a blanket
o keep them warm for an additional 30min. All
atients were weighed before and after the ther-
py, thereafter oral hydration with water was used
o compensate for the lost weight.
Waon therapy was performed once a day, 5 days
week for 4 weeks, a total of 20 times. To rule
ut acute effects of Waon therapy, all examinations
ere performed before the ﬁrst treatment and on
he next day after the last treatment.
easurementshysical examinations
he blood pressure (BP), pulse rate, body weight
nd body temperature were measured before and
fter Waon therapy.
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Cardiac function tests
Echocardiography was performed to evaluate the
cardiac function and to determine the tricus-
pid regurgitation speeds by the continuous wave
Doppler echocardiography, in which the pulmonary
systolic pressure was estimated by the use of
Bernoulli’s equation. The LV and RV functions
were analyzed by the Tei index, the sum of
isovolumetric contraction time and isovolumetric
relaxation time divided by ejection time [10].
Right ventricular (RV) positive dP/dt at rest was
assessed by using tricuspid regurgitation (TR)
estimated with Doppler echocardiography before
and after Waon therapy. Two points at 1.0 and
2.0m/s were selected on the rising segment of
the TR velocity curve and the time interval (t)
between them was measured. The increase in
instantaneous velocity between the two points
was converted to RV-right atrial pressure gradient
(P) using the simpliﬁed Bernoulli equation. The
rate of RV pressure rise was obtained as P/t
[11].
In addition, we performed echocardiograms dur-
ing ergometer exercise to monitor the changes in
the pulmonary arterial pressure. Studied patients
pedaled a bicycle (Aerobic Exercise Ergometer, STB-
1200; Nihon Kohden; Tokyo, Japan) with a 10W
load for 3min and after that, the load of the bicy-
cle increased by 10W for additional every 3min.
And they kept pedaling at the speed of 60 rpm
and were encouraged to continue exercising for
as long as possible. We recorded TR velocity by
the continuous wave Doppler echocardiogram every
3min.
We evaluated exercise tolerance by ergometer.
At ﬁrst, the patients pedaled a bicycle without a
A
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Table 1 Patient’s proﬁle
Case Age Gender Height (cm) BW (kg) BMI (kg/m
1 67 M 161.5 56.0 20.5
2 73 M 155.0 37.4 15.6
3 80 M 160.9 70.3 27.1
4 69 M 156.0 47.0 19.3
5 67 M 166.3 61.5 22.2
6 76 M 166.1 43.4 15.7
7 76 M 163.7 43.4 16.1
8 86 M 161.8 54.5 20.8
9 77 M 159.8 46.0 18.0
10 79 M 150.6 51.1 22.7
11 71 M 163.0 49.0 18.4
12 75 M 164.0 56.2 20.9
13 78 M 155.4 57.2 23.7
M, male; BW, body weight; BMI, body mass index; GOLD, Global In
Research Council; SI, smoking index.M. Umehara et al.
oad for 3min and after that, the load of a bicy-
le increased by 10W every minute. They pedaled
bicycle at the speed of 60 rpm. The patients
ere encouraged to continue exercising for as long
s possible. The test was terminated at symptom
imitation or if there were any safety concerns.
e monitored oxygen saturation by pulse oximeter
SpO2), BP, heart rate (HR) and ECG during exer-
ise.
t. George’s Respiratory Questionnaire
SGRQ) scores
he health-related quality of life was evaluated
ith the Japanese versions of St. George’s Respi-
atory Questionnaire (SGRQ) which is a measure
f impaired health in disease of chronic airﬂow
imitation. SGRQ contains 50 items that can be
ivided into three dimensions (symptoms, activity
nd impacts), and their scores ranged from 0 to 100
worst status) [12].
aboratory measurements
blood sample was obtained to measure the plasma
evels of the brain natriuretic peptide (BNP) with a
adioimmunoassay, hematocrit and albumin before
nd after repeated Waon therapy.
tatistical analysisll data are expressed as the mean value± S.D. The
ata before and after Waon therapy were compared
sing the paired Student’s t-test. A p-value of <0.05
as considered to be signiﬁcant.
2) %FEVI GOLD stage MRC scale SI (pak-year)
18.9 IV 5 88
34.3 IV 5 68
34.2 IV 5 50
34.4 III 4 34
11.9 IV 5 60
40.2 IV 5 92
37.5 IV 5 46
48.5 III 5 45
37.5 III 5 61
51.5 II 4 60
39.7 IV 4 45
61.2 IV 4 80
57.5 II 4 114
itiative for Chronic Obstructive Lung Disease; MRC, Medical
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Table 2 Physical ﬁndings and laboratory examinations
Before therapy After therapy p-Value
BW (kg) 50.8 ± 7.8 50.9 ± 7.8 0.926
HR (bpm) 86 ± 9 85 ± 13 0.820
SBP (mmHg) 130 ± 17 120 ± 15 0.002
DBP (mmHg) 74 ± 9 69 ± 8 0.0002
Hematocrit (%) 40.3 ± 9.2 40.0 ± 8.5 0.617
Alb (g/dl) 4.1 ± 0.3 4.1 ± 0.3 1.0
; SBP
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hBNP (pg/ml) 25.7 ± 19.6
Value given as mean± S.D.; BW, body weight; HR, heart rate
albumin; BNP, brain natriuretic peptide.
esults
linical characteristics
he clinical characteristics of 13 patients are sum-
arized in Table 1. All patients were male with a
ean age of 74.9± 5.5 years (range, 67—86 years).
he mean BMI was 20.1± 3.4, and the mean %FEV1
as 39.0± 13.8%. They were all past smokers.
ccording to the GOLD classiﬁcation, eight patients
ere in stage IV (very severe), while 3 patients were
n stage III (severe), and the other 2 patients were
n stage II (moderate). Eight patients were MRC dys-
nea scale grade 5 and 5 patients were grade 4.
ffects of Waon therapy on body weight,
eart rate, blood pressure and laboratory
ariables
e performed repeated Waon therapy without
ny problems for all enrolled patients. None of
he patients experienced dyspnea in the sauna
oom. Physical ﬁndings and laboratory examina-
ions before and after repeated Waon therapy
re demonstrated in Table 2. All patients did not
ave any cardiac disorders either during or after
aon therapy. The mean body weight and the
ean HR did not substantially change before and
fter Waon therapy. On the other hand, systolic
E
T
r
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Table 3 Echocardiographic parameters
Before therapy
LVDd (mm) 41.0 ± 5.7
LAD (mm) 30.3 ± 7.2
EF (%) 68.8 ± 8.8
LV Tei index 0.41 ± 0.08
RV Tei index 0.51 ± 0.15
Systolic PAP (mmHg) 41.0 ± 8.3
IVC (mm) 9.2 ± 1.5
RV dP/dt (mmHg/s) 397 ± 266
Value given as mean± S.D.; EF, ejection fraction; PAP, pulmonary a21.3 ± 13.4 0.294
, systolic blood pressure; DBP, diastolic blood pressure; Alb,
nd diastolic blood pressure decreased signiﬁcantly
systolic blood pressure: 130± 17 to 120± 15,
= 0.002; diastolic blood pressure: 74± 9 to 69± 8,
= 0.0002) after Waon therapy. The hematocrit,
lbumin and plasma BNP concentrations did not
hange. The MRC dyspnea scale grades did not
hange. In addition, the liver function, renal func-
ion and electrolytes did not change after Waon
herapy (data not shown).
ardiac function
ardiac function was evaluated by the use of
chocardiography before and after repeated Waon
herapy. The ejection fraction and systolic pul-
onary artery (PA) pressure at rest did not change
fter the therapy in comparison to baseline. The
V Tei index tended to decrease after the therapy
0.51± 0.15 to 0.46± 0.11, Table 3). RV posi-
ive dP/dt elevated signiﬁcantly from 397± 266
o 512± 320mmHg/s (p = 0.024) after the therapy
Table 3). No patients had any symptoms or signs of
eart failure during this therapy.xercise tolerance
he PA pressure at rest did not improved after
epeated Waon therapy. However, the PA pres-
ure during exercise decreased signiﬁcantly after
After therapy p-Value
39.2 ± 5.6 0.184
28.8 ± 8.7 0.923
67.8 ± 8.8 0.602
0.43 ± 0.13 0.534
0.46 ± 0.11 0.169
37.4 ± 6.4 0.168
9.3 ± 1.6 0.675
512 ± 320 0.024
rtery pressure.
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Figure 1 PA pressure during exercise (A) and exercise time (
of pulmonary arterial pressure during exercise decreased sign
of exercise. The exercise time signiﬁcantly prolonged after W
repeated Waon therapy in comparison to base-
line (64.0± 18.0 to 51.3± 13.1mmHg, p = 0.028),
with the same loading dose of exercise (Fig. 1A).
The exercise time also signiﬁcantly increased
after repeated Waon therapy (359.6± 106.5 to
391.5± 97.0 s, p = 0.032) (Fig. 1B). In addition,
the lowest SpO2 during exercise signiﬁcantly ele-
vated after the therapy (89.4± 4.8 to 91.3± 4.1%,
p = 0.022) (Fig. 2).
St. George’s Respiratory Questionnaire
(SGRQ) scores measurements
SGRQ scores were measured to evaluate the change
of QOL, which is consisted of 50 questionnaires
Figure 2 Changes of SpO2 during exercise before and
4 weeks after Waon Therapy. SpO2 during exercise is
increased signiﬁcantly.
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tB) before and after 4 weeks of Waon Therapy. The mean
iﬁcantly after Waon therapy with the same loading dose
aon therapy. PA = pulmonary artery.
bout symptoms, activity and impacts, before and
fter the repeated Waopn therapy. The symptoms
cores signiﬁcantly decreased after repeated Waon
herapy in comparison to baseline (67.7± 20.6
o 56.5± 23.5, p = 0.007). In addition, the total
cores and the impacts scores in SGRQ signiﬁcantly
ecreased (59.7± 16.9 to 55.3± 17.2, p = 0.002,
3.7± 21.8 to 40.1± 21.2, p = 0.024). The activity
cores tend to decrease (83.3± 16.4 to 81.2± 15.0)
Fig. 3).
In contrast, the MRC did not change because it is
questionnaire only about dyspnea.
iscussion
his is the ﬁrst report to demonstrate that Waon
herapy regimen improves PH during exercise, exer-
ise time, in addition, the symptoms, impacts and
otal scores of SGRQ in the patients with severe
OPD.
We suppose that the prolongation of exercise
ime by Waon therapy is related to the pulmonary
rterial pressure during exercise, not at rest. An
mprovement of ventilation competence may be
elated to the prevention of desaturation during
xercise. Previous studies have identiﬁed a number
f mechanisms for exercise-induced PH in COPD,
ncluding hypoxic vasoconstriction, reduction of the
apillary bed by emphysema, extramural compres-
ion by increased alveolar pressure or impaired
elease of endothelium-derived relaxing factors.
hese factors may together contribute to the
evelopment of PH during exercise, and dynamic
yperinﬂation due to the expiratory ﬂow limitation
hat results in increased alveolar pressure [13—16].
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oigure 3 Changes of SGRQ symptoms score (A), activit
eeks after Waon Therapy. The symptoms, the impacts
aon therapy. SGRQ= St. George’s Respiratory Questionn
Kubo et al. examined the relationship between
essel remodeling and the physiology of pulmonary
irculation in severe COPD patients who underwent
ung-volume-reduction surgery [17]. They analyzed
he pulmonary hemodynamics at rest and during
xercise, and the morphology of the pulmonary
rteries in these patients. As a result, they have
escribed that pulmonary artery remodeling leads
o a reduced recruitability and distensibility of
he pulmonary vessels and it is therefore closely
elated to exercise PH. Therefore, they suggested
hat the degree of the remodeling cannot be esti-
ated by the resting pulmonary artery pressure.
he expression of eNOS in pulmonary arteries is
educed in COPD patients with PH [18] and also
n smokers [19]. The diminished synthesis of nitric
xide may contribute to the alterations in the struc-
ure and endothelial function of pulmonary vessels
n cigarette-smoke-induced respiratory disease. In
ddition, the structural and functional changes of
ulmonary circulation are apparent at the initial
tages of COPD [19]. Recent investigations have
hown endothelial dysfunction and the changes in
he expression of endothelium-derived mediators
hat regulate vascular tone and cell growth in the
ulmonary arteries of patients with mild COPD.
he expression of eNOS decreases in the pulmonary
rteries of COPD patients with pulmonary hyperten-
ion [20].
We previously demonstrated that the gene
xpression and protein level of eNOS increase sig-
iﬁcantly in the peripheral arteries from the golden
amster after 4-week repeated Waon therapy [9].
oreover, we also reported this therapy improves
he impaired vascular endothelial function in a
etting of coronary risk factors [6]. We suggest
hat this therapy improves endothelial function in
s
b
t
rre (B), impacts score (C), total score (D) before and 4
the total scores signiﬁcantly decreased after repeated
OPD patients in the same way. The signiﬁcant
ecrease in BP after this therapy is probably due
o an improved endothelium-dependent vasodila-
ion. Anconina et al. described RV dP/dt provides
reliable noninvasive index to approach RV con-
ractility [11]. According to our data, RV dP/dt
levated signiﬁcantly after the therapy, suggest-
ng the improvement of RV contractility. We expect
hat Waon therapy increase the expression of eNOS
n PA, and improve PA vascular function. Thereafter,
V contractility improved by reducing the afterload
f RV. As a result, we therefore assume that the
H during exercise and the exercise tolerance also
mproved.
The present study indicates that 4-week Waon
herapy regimen was found to improve symptoms
nd QOL in patients with COPD. Oga et al. reported
he SGRQ total score to be a predictive factor
f mortality, independent of FEV1 and age [21].
n addition, Domingo-Salvany et al. reported the
GRQ total score to be independently associated
ith the total and respiratory mortality in Cox
odels, including age, FEV1, and BMI [22]. It was
lso notable that the SGRQ total score improved
y Waon therapy in 4 weeks. Improvements in
he symptoms score contributed to most of the
mprovements in the total score. We previously
eported that a self-assessment QOL of the patients
ith chronic heart failure improved after this ther-
py [8]. In the items of a concrete questionnaire
egarding symptoms, the frequency of a cough,
espiratory symptomatic frequency and the period
f being well conditioned were improved in this
tudy. Ernst et al. suggested that regular sauna
athing may reduce the incidence of acute respira-
ory infections [23]. No patient demonstrated any
espiratory tract infection during this study.
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Masuda et al. reported that repeated Waon ther-
apy may be useful for mildly depressed patients
with appetite loss and other subjective complaints
[24]. Patients with severe COPD are at an increased
risk of developing depression [25]. We therefore
suppose that this therapy may diminish the psy-
chological distress in patients with COPD. Further
studies are needed to investigate the change in the
SGRQ scores and the frequency of acute exacerba-
tions by continuing Waon therapy for a longer time
period.
Study limitations
This study is not a case—control study and the
study group was also very small. As a result,
it remains necessary to investigate more COPD
patients, including those with mild COPD. We also
need to evaluate the airway inﬂammation in COPD
after this therapy.
In addition, we need a further evaluation of
the vascular endothelial function and changes in
the pulmonary arterial pressure in COPD by con-
tinuing such Waon therapy for a longer period of
time.
Conclusion
The repeated Waon therapy was thus found to
improve the RV positive dP/dt, PH during exercise,
exercise tolerance and SGRQ scores in the patients
with severe COPD. This therapy may therefore be
a novel, safe, and promising therapy for patients
with severe COPD.
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